- Defence Therapeutics Inc. (DTC), completed good laboratory studies related to its anti-cancer AccuTOX molecule
- AccuTOX effectively killed a large set of tumours in human and rodent samples
- This compound also gave indication that it can be used to treat a variety of cancers
- The studies also found that AccuTOX was well tolerated at continuous high dosages during animal testing
- Defence Therapeutics Inc. (DTC) is up 1.50 per cent, trading at $2.03 per share as of 9:55 a.m. EST
Defence Therapeutics (DTC) has completed good laboratory studies related to its anti-cancer AccuTOX molecule and will move this work to a phase one trial.
For the past 16 months, Defence has created a library of its original Accum variants exhibiting differential effects on both immune and cancer cells.
One of the lead molecules proved to be AccuTOX, a small compound which effectively killed a large set of tumours in human and rodent samples. This compound also gave an indication that it can be used to treat a variety of cancers.
The studies also found that there were no adverse side effects for AccuTOX during rodent testing and it was well tolerated even at continuous high dosages. Defence then followed up with a second set of studies in Beagle dogs with even higher doses, where it found repetitive doses were well tolerated aside from mild skin reactions on the injected area.
Sebastien Plouffe, CEO of Defence, commented,
“The molecule is highly effective as an anti-cancer molecule and exhibits no toxic effects in different animal models… that dogs can tolerate AccuTOX up to 100 milligrams per kilogram demonstrates a larger than the expected therapeutic window for this treatment.”
The company is planning to meet with the U.S. Food and Drug Administration in the next few weeks to secure approval for launching its phase one trial against solid tumours.
The trial will test the safety and tolerability of the drug in cancer patients and assess some form of potency as a secondary objective.
Defence TheraDefence Therapeutics Inc. (DTC) is up 1.50 per cent, trading at $2.03 per share as of 9:55 a.m. EST.
